beta-alanine has been researched along with Cardiovascular Diseases in 16 studies
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The primary objective was to assess the cost-effectiveness of new oral anticoagulants compared with warfarin in patients with nonvalvular atrial fibrillation." | 8.89 | Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. ( Cameron, C; Coyle, D; Coyle, K; Kelly, S; Lee, K; Steiner, S; Wells, GA, 2013) |
| "Dabigatran is an oral thrombin inhibitor which has been approved for prevention of stroke or embolism in atrial fibrillation patients as an alternative to vitamin K antagonists." | 7.80 | Life-threatening epistaxis and red blood cell polyagglutination under dabigatran. ( Finsterer, J; Krutisch, G; Stöllberger, C, 2014) |
| "Alternative anticoagulants to warfarin (dabigatran, rivaroxaban, and apixaban) are becoming available for the prevention of thromboembolic stroke in atrial fibrillation (AF), but there is a lack of information on their comparative effectiveness." | 7.79 | Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation. ( Hughes, DA; Pink, J; Pirmohamed, M, 2013) |
| " Three non-VKA oral anticoagulants (OACs), dabigatran, rivaroxaban and apixaban, are available for the prevention of stroke in patients with atrial fibrillation (AF) and may change clinical practice." | 4.90 | Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions. ( Barillari, G; Cheng, JW, 2014) |
| "The primary objective was to assess the cost-effectiveness of new oral anticoagulants compared with warfarin in patients with nonvalvular atrial fibrillation." | 4.89 | Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. ( Cameron, C; Coyle, D; Coyle, K; Kelly, S; Lee, K; Steiner, S; Wells, GA, 2013) |
| " Dabigatran: elderly patients with renal failure are at higher risk of bleeding." | 4.89 | [Pharmacovigilance update]. ( Livio, F, 2013) |
| "Dabigatran is an oral thrombin inhibitor which has been approved for prevention of stroke or embolism in atrial fibrillation patients as an alternative to vitamin K antagonists." | 3.80 | Life-threatening epistaxis and red blood cell polyagglutination under dabigatran. ( Finsterer, J; Krutisch, G; Stöllberger, C, 2014) |
| "Alternative anticoagulants to warfarin (dabigatran, rivaroxaban, and apixaban) are becoming available for the prevention of thromboembolic stroke in atrial fibrillation (AF), but there is a lack of information on their comparative effectiveness." | 3.79 | Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation. ( Hughes, DA; Pink, J; Pirmohamed, M, 2013) |
| "The patient, who had unresectable colon cancer metastases to the liver and lung, was referred to us for chemotherapy from an affiliated hospital; he had no cardiac history." | 1.33 | 5-Fluorouracil cardiotoxicity induced by alpha-fluoro-beta-alanine. ( Hatakeyama, K; Muneoka, K; Shirai, Y; Wakai, T; Yokoyama, N, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 13 (81.25) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Craig, A | 1 |
| Kruger, R | 1 |
| Gafane-Matemane, LF | 1 |
| Louw, R | 1 |
| Mels, CMC | 1 |
| Agewall, S | 1 |
| Cattaneo, M | 1 |
| Collet, JP | 1 |
| Andreotti, F | 1 |
| Lip, GY | 1 |
| Verheugt, FW | 1 |
| Huber, K | 1 |
| Grove, EL | 1 |
| Morais, J | 1 |
| Husted, S | 1 |
| Wassmann, S | 1 |
| Rosano, G | 1 |
| Atar, D | 1 |
| Pathak, A | 1 |
| Kjeldsen, K | 1 |
| Storey, RF | 1 |
| Stiefelhagen, P | 1 |
| Attia, JR | 1 |
| Pearce, R | 1 |
| McKenzie, JL | 1 |
| Douglas, G | 1 |
| Bazargan, A | 1 |
| Pink, J | 1 |
| Pirmohamed, M | 1 |
| Hughes, DA | 1 |
| Coyle, D | 1 |
| Coyle, K | 1 |
| Cameron, C | 1 |
| Lee, K | 1 |
| Kelly, S | 1 |
| Steiner, S | 1 |
| Wells, GA | 1 |
| Lega, JC | 1 |
| Bertoletti, L | 1 |
| Durupt, S | 1 |
| Epinat, M | 1 |
| Mismetti, P | 1 |
| Da Costa, A | 1 |
| Laporte, S | 1 |
| Stöllberger, C | 1 |
| Krutisch, G | 1 |
| Finsterer, J | 1 |
| Cheng, JW | 1 |
| Barillari, G | 1 |
| Ing, E | 1 |
| Douketis, J | 1 |
| Warkentin, TE | 1 |
| Margetts, P | 1 |
| Connolly, SJ | 1 |
| Lamy, A | 1 |
| Ricci, C | 1 |
| Eikelboom, JW | 1 |
| Rami, BK | 1 |
| Livio, F | 1 |
| Muneoka, K | 1 |
| Shirai, Y | 1 |
| Yokoyama, N | 1 |
| Wakai, T | 1 |
| Hatakeyama, K | 1 |
| Rashid, I | 1 |
| van Reyk, DM | 1 |
| Davies, MJ | 1 |
6 reviews available for beta-alanine and Cardiovascular Diseases
| Article | Year |
|---|---|
Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy.
Topics: Adenosine; Aspirin; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Clopidogrel; Dabigatran; | 2013 |
Perioperative management of anticoagulation in elective surgery.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Cardiovascular Di | 2013 |
Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Ben | 2013 |
Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Ca | 2014 |
New oral anticoagulants and oculoplastic surgery.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Catarac | 2014 |
[Pharmacovigilance update].
Topics: Adrenergic Uptake Inhibitors; Age Factors; Aged; Amides; Antihypertensive Agents; Atomoxetine Hydroc | 2013 |
10 other studies available for beta-alanine and Cardiovascular Diseases
| Article | Year |
|---|---|
Early vascular ageing phenotypes and urinary targeted metabolomics in children and young adults: the ExAMIN Youth SA and African-PREDICT studies.
Topics: Adult; Aging; beta-Alanine; Blood Pressure; Cardiovascular Diseases; Child; Child, Preschool; Histid | 2023 |
[Your patient needs antithrombotics, 2. What do the new substances offer? (interview by Dr. med. Peter Stiefelhagen)].
Topics: Adenosine; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Clopidogrel; | 2013 |
The use, misuse and abuse of dabigatran.
Topics: Advertising; Anticoagulants; Antithrombins; Aspirin; Australia; Benzimidazoles; beta-Alanine; Cardio | 2013 |
Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation.
Topics: Age Factors; Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular | 2013 |
[New oral anticoagulants in nonvalvular atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascu | 2013 |
Life-threatening epistaxis and red blood cell polyagglutination under dabigatran.
Topics: Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular | 2014 |
Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding.
Topics: Aged; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Dabigatran; Factor VIIa; Humans; Male; | 2012 |
Direct thrombin inhibitors' potential efficacy in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Cardiovascular | 2012 |
5-Fluorouracil cardiotoxicity induced by alpha-fluoro-beta-alanine.
Topics: Aged; Antimetabolites, Antineoplastic; beta-Alanine; Cardiovascular Diseases; Colonic Neoplasms; Dru | 2005 |
Carnosine and its constituents inhibit glycation of low-density lipoproteins that promotes foam cell formation in vitro.
Topics: beta-Alanine; Cardiovascular Diseases; Carnosine; Diabetic Angiopathies; Foam Cells; Glycosylation; | 2007 |